Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Patients With T2D Presenting With Glycosuria: Examining the

SGLT2 MOA

Goals

Diagnosed Diabetes, 1958-2010

Despite Increasing Prevalence, T2D Remains Undertreated

Limitations of Conventional Glucose-Lowering Agents

Limitations of Conventional Glucose-Lowering Agents (cont)

The Need for Novel Antihyperglycemic Agents

Pathophysiologic Pathways Affecting Glycemic Control in

T2D

SGLT2 and Glucose Control

SGLT2: Novel Target for Glucose Control

Currently FDA-approved SGLT2 Inhibitors

Glycosuria: Concerns in Urgent Care Settings

Clinical Trial Findings for SGLT2 Inhibitors

Clinical Trial Findings for SGLT2 Inhibitors: Extraglycemic Effects

SGLT2 Inhibitors: Risk of Hypotension

Treating Patients With Type 2 Diabetes and CKD

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)